Staging preview: health content pending qualified review
D2C Peptides
HGH Fragment 176-191 vial

HGH Fragment 176-191 2 mg

Also searched as: hgh frag 176-191, frag 176-191

Sold as Frag (176-191) - 2mg

$30 In stock

Strength
Ships from

For research use only. Not for human or veterinary use.

Ships from the USA or Canada. Shipping details

HGH Fragment 176-191 is a synthetic peptide copying the last 16 amino acids of human growth hormone (positions 176 to 191), looped by one disulfide bond.12 Neither it nor its tyrosine-modified relative AOD-9604 is an approved drug,34 and ClinicalTrials.gov lists no human trial of the fragment.5 This vial holds 2 mg of white freeze-dried solid; the supplier's listing gives the AOD-9604 sequence.67

Specifications

Sequence, native fragment (one-letter code)FLRIVQCRSVEGSCGF, with a disulfide bond between Cys7 and Cys1412
Sequence, native fragment (three-letter code)H-Phe-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-OH1
Sequence listed by the supplierTyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, which is the AOD-9604 sequence (YLRIVQCRSVEGSCGF)67
Length16 amino acids: positions 176 to 191 of the 191-amino-acid human growth hormone18
Molecular formulaC78H123N23O22S2 (free peptide); C80H127N23O24S2 (acetate salt); the supplier lists C78H125N23O23S296
Molar mass1799.1 g/mol (free peptide); 1859.1 g/mol (acetate salt); the supplier lists 1817.1 g/mol96
CAS number66004-57-7 (the supplier lists the same number)106
PubChem CID16131230 (Somatotropin (176-191)); 172966176 (acetate salt)101
FormWhite lyophilized (freeze-dried) solid, as listed by the supplier6
Vial contents2 mg per vial; no diluent included6
Strength2 mg
Ships fromUSA, Canada
CategoryWeight Loss Peptides
StorageShelf life per the supplier: 36 months frozen at -20 °C or 30 days refrigerated at 2 to 8 °C, with the solution kept in the refrigerator after reconstitution.6 No published stability study of the fragment was found.

Supplies for HGH Fragment 176-191

Bulk and wholesale orders

Research groups that need HGH Fragment 176-191 in volume can apply for a wholesale account, with bulk terms confirmed on application.

Wholesale detailsApply for a wholesale account

Questions about HGH Fragment 176-191

About HGH Fragment 176-191

HGH Fragment 176-191 is the tail end of human growth hormone, positions 176 to 191 of the 191-amino-acid hormone, made in the lab.18 Its two cysteines form one disulfide bond, which closes the chain into a loop.1 Its close relative AOD-9604 is hGH 177-191 with a tyrosine added at the front,3 so the two peptides differ only in their first amino acid.17

The names get mixed up: a 2026 review notes that AOD-9604 is sometimes labeled hGH 176-191,4 and the supplier of this vial lists the AOD-9604 sequence under the fragment's name.6

This page lists HGH Fragment 176-191 for sale as a 2 mg research vial, and the selector above shows the HGH Fragment 176-191 price and stock by shipping origin. Before you buy HGH Fragment 176-191 for a study, What is HGH Fragment 176-191? covers the evidence, side effects and full source list.

Research highlights

  • Normal rats (1978): synthetic hGH 176-191 and three related tail fragments each caused a short-lived rise in blood glucose and a longer rise in insulin.13
  • Rats (1993): hGH 177-191 reduced fat production as much as the whole hormone did, but showed no significant fat-breakdown effect.14
  • Obese mice (1994): long-term treatment with hGH 177-191 reduced cumulative weight gain and fat tissue mass.15
  • Obese rats (2000): 20 days of AOD9401, a synthetic hGH 177-191, reduced weight gain and cut average fat-cell diameter from 110 to 80 micrometers, without causing insulin resistance.16
  • Breast cancer cells (2022): adding hGH fragment 176-191 to doxorubicin-loaded nanoparticles increased their growth-slowing effect on MCF-7 cells, in a drug-delivery study rather than a fat-loss study.17
  • People: ClinicalTrials.gov lists no trial of the native fragment.5 Its tyrosine version, AOD-9604, showed no significant weight loss versus placebo in a trial that enrolled 536 adults with obesity.3

Regulatory status

Neither hGH 176-191 nor AOD-9604 is an approved drug,34 and the supplier states its products are not evaluated by FDA.6 The fragment does not appear on FDA's May 14, 2026 list of substances nominated for pharmacy compounding.18 For AOD-9604, FDA's compounding advisory committee voted 12 to 0 in December 2024 against adding it to the 503A bulks list.19 The 2026 WADA Prohibited List names hGH 176-191 under S2.2.3, growth hormone fragments, banned at all times in and out of competition.12 The vial carries this label: For research use only. Not for human or veterinary use.

Handling and storage

No published solubility or post-mixing stability figure for the native fragment was found. For AOD-9604, a supplier certificate cited by FDA lists water solubility up to 2 mg per mL, and FDA notes that its disulfide bridge can break down and that heat or pH changes can make it aggregate.3 In blood samples, both peptides were extensively degraded after a week at 4 °C but stayed stable for at least two months at -20 °C.20 Lab steps are in How to reconstitute a peptide vial, the AOD-9604 figures in How to reconstitute AOD-9604, and the reconstitution calculator does the division.

Frequently asked questions

What strength of HGH Fragment 176-191 is available, and where does it ship from?

One strength is listed: 2 mg per vial, from $30. Orders ship from the USA and Canada to addresses across the United States. The selector above shows stock for each shipping origin before the vial goes in the cart. Delivery options are on the shipping page and return terms on the returns page.

How should HGH Fragment 176-191 be stored when it arrives?

The supplier's longest shelf life is frozen: 36 months at -20 °C, against 30 days at 2 to 8 °C.6 It does not say whether the 30 days applies before or after mixing, and it says to refrigerate the solution after reconstitution.6 For the closely related AOD-9604 acetate, supplier documents cited by FDA recommend -20 °C, with 2 to 8 °C only for storage under six months.3

Is this vial the native fragment or AOD-9604?

The listing does not settle it. The native fragment starts with phenylalanine (FLRIVQCRSVEGSCGF), while AOD-9604 starts with tyrosine (YLRIVQCRSVEGSCGF).17 The supplier names the product Frag (176-191) but lists the tyrosine sequence with the native fragment's CAS number, and a formula and molar mass that match neither PubChem record.6109 A certificate reporting a measured mass can be compared with PubChem's 1799.1 g/mol for the native peptide and 1815.1 g/mol for AOD-9604.9

Is there a certificate of analysis for HGH Fragment 176-191?

Certificate information is on the lab results page, and a specific lot can be asked about through the contact page. Read which tests a certificate reports, not only its purity figure: for AOD-9604, FDA found that a certificate submitted with a nomination gave no results for impurities, aggregates, microbial limits or bacterial endotoxin.3

What supplies are used with an HGH Fragment 176-191 vial?

No diluent comes with the vial, so the solid is mixed with a measured volume of liquid before lab work.6 Listed with this product are bacteriostatic water, a 3 mL Luer-Lok syringe, an 18G 1-inch needle, insulin syringes and alcohol swabs.

Is HGH Fragment 176-191 for human use?

No. It is a laboratory research vial, labeled: For research use only. Not for human or veterinary use. ClinicalTrials.gov lists no trial of the native fragment,5 and the only human trials found used AOD-9604, given by mouth or by vein.11 FDA found no information on injecting AOD-9604 under the skin in humans.3 WADA bans hGH 176-191 in sport at all times.12

Written by D2C Peptides Editorial Team.

Pending qualified review.

Updated .

Sources

  1. HGH Fragment 176-191 (PubChem CID 172966176): Biologic Description. PubChem, National Library of Medicine (NIH), 2026.
  2. UniProtKB P01241 (SOMA_HUMAN), Somatotropin: FASTA sequence. UniProt Consortium, 2026.
  3. FDA Briefing Document, Pharmacy Compounding Advisory Committee, December 4, 2024: Evaluation of AOD-9604-related bulk drug substances. U.S. Food and Drug Administration, 2024.
  4. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Dominikowski A et al.), full text. Frontiers in Endocrinology (via PubMed Central, NLM), 2026.
  5. ClinicalTrials.gov API v2 search: "176-191" OR "HGH fragment" OR "growth hormone fragment" OR AOD9604 OR "AOD-9604" (no registered studies). ClinicalTrials.gov, National Library of Medicine (NIH), 2026.
  6. Supplier product specification.
  7. Aod-9604 (PubChem CID 71300630): Biologic Description. PubChem, National Library of Medicine (NIH), 2026.
  8. GENOTROPIN (somatropin) for injection, prescribing information (DailyMed, August 2026 version). DailyMed, National Library of Medicine (Pfizer label), 2026.
  9. PubChem computed properties for CIDs 172966176, 172966177, 16131230 and 71300630. PubChem, National Library of Medicine (NIH), 2026.
  10. Somatotropin (176-191), PubChem CID 16131230: full compound record (CAS, MeSH entry terms, synonyms). PubChem, National Library of Medicine (NIH), 2026.
  11. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans (Stier H, Vos E, Kenley D); authors tied to the developer, Metabolic Pharmaceuticals. Journal of Endocrinology and Metabolism (Elmer Press), 2013.
  12. Tractatenblad 2026, 25: Anti-doping convention (ETS No. 135), amendment to the appendix: The 2026 Prohibited List, World Anti-Doping Code. Kingdom of the Netherlands, Ministry of Foreign Affairs (official publication of the WADA 2026 Prohibited List), 2026.
  13. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone (Ng FM, Bornstein J), PubMed abstract. American Journal of Physiology (via PubMed, NLM), 1978.
  14. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone (Wu Z, Ng FM), PubMed abstract. Biochemistry and Molecular Biology International (via PubMed, NLM), 1993.
  15. Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide (Natera SH et al.), PubMed abstract. Biochemistry and Molecular Biology International (via PubMed, NLM), 1994.
  16. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats (Ng FM et al.), PubMed abstract. Journal of Molecular Endocrinology (via PubMed, NLM), 2000.
  17. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells (Habibullah MM et al.), PubMed abstract. Drug Design, Development and Therapy (via PubMed, NLM), 2022.
  18. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026). U.S. Food and Drug Administration, 2026.
  19. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. U.S. Food and Drug Administration, 2024.
  20. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices (Mazzarino M et al.), PubMed abstract. Analyst (via PubMed, NLM), 2026.
Shop all peptidesMore weight loss peptides